The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial

ConclusionsThe application of 1% DHL-HisZnNa to the scalp did not prevent CIA. However, this drug may promote recovery from CIA.Trial registration number: UMIN000014840.

Source: Breast Cancer Research and Treatment - February 26, 2019 Category: Cancer & Oncology Source Type: research